Treatment of inflammatory disorders
AssigneeSetPoint Medical Corporation
InventorsJacob A. Levine, David Chernoff, Murthy V. Simhambhatla
Life of this patent
Estimating the term…
Abstract
Methods and apparatuses for treating inflammatory diseases by neurostimulation in patients who have failed to adequately respond or have become intolerant to a drug therapy (such as a TNF inhibitor and/or a JAK inhibitor).
Claims20
A method of reducing inflammation in a patient that is intolerant to or has failed to respond to Tumor Necrosis Factor (“TNF”) inhibition, the method comprising:
- identifying that the patient has failed to respond to TNF inhibitor therapy comprising a drug that inhibits TNF;
- and
- administering a treatment regimen by applying electrical energy to activate a neuroimmune anti-inflammatory pathway in the patient to restore the efficacy of the drug that inhibits TNF;
- and
- treating the patient with the drug that inhibits TNF concurrent with or following restoration of the efficacy of the drug that inhibits TNF.
A method of reducing inflammation in a patient that is intolerant to or has failed to adequately respond to either Tumor Necrosis Factor (“TNF”) inhibition, the method comprising:
- identifying that the patient has failed to respond to TNF inhibitor therapy comprising a drug that inhibits TNF;
- administering a treatment regimen to restore the efficacy of the drug that inhibits TNF by activating a neuroimmune anti-inflammatory pathway in the patient by applying electrical energy to one of:
- a vagus nerve, a splenic nerve, a radial nerve, a median nerve, an ulnar nerve, a femoral nerve, a sciatic nerve, a tibial nerve, a splanchnic nerve, a phrenic nerve, a hepatic nerve, a renal nerve, a greater auricular nerve, a lesser occipital nerve, or an auriculotemporal nerve, wherein applying electrical energy comprises applying charge ranging from 0.2 nanocoulombs and 5 kilocoulomb per hour;
- and
- treating the patient with the drug that inhibits TNF concurrent with or following restoration of the efficacy of the drug that inhibits TNF.
A method of reducing inflammation in a patient that is intolerant to or has failed to respond to Tumor Necrosis Factor (“TNF”) inhibition, the method comprising:
- identifying that the patient has failed to respond to TNF inhibitor therapy comprising a drug that inhibits TNF;
- administering a treatment regimen to activate a neuroimmune anti-inflammatory pathway in the patient to restore the efficacy of the drug that inhibits TNF by applying energy to one of:
- a vagus nerve, a splenic nerve, a radial nerve, a median nerve, an ulnar nerve, a femoral nerve, a sciatic nerve, a tibial nerve, a splanchnic nerve, a phrenic nerve, a hepatic nerve, a renal nerve, a greater auricular nerve, a lesser occipital nerve, or an auriculotemporal nerve;
- and
- administering, concurrent with or after the application of energy to restore the efficacy of the drug, the same drug, or a drug of the same class that inhibits TNF that the patient had previously failed to respond to.
Dependencies are inferred from the claim text.